Clinical Trial Update: A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and antiviral effect of ABT-493 and ABT-530 in adults with genotype 1 hepatitis C, completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493
• ABT-530

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2017-10-16